Clover Biopharmaceuticals Ltd (Clover; HKEX: 02197), a China-based global commercial-stage biotechnology company, announced on Sunday that it has received IND approval from USFDA for its SCB-1019, a non-adjuvanted bivalent RSV prefusion-stabilised F (PreF)-Trimer subunit vaccine candidate based on Clover's Trimer-Tag vaccine technology platform.
The company has also completed enrolment of the first participants in a phase one revaccination clinical trial of SCB-1019.
The ongoing Phase I revaccination trial in the US is enrolling up to 160 older adults (60-85 years) who previously received an initial dose of GSK's RSV vaccine (AREXVY) at least 2 seasons prior, and participants will be randomised to receive either a heterologous revaccination dose of SCB-1019, a homologous AREXVY revaccination dose or saline placebo. The study will assess safety, reactogenicity and immunogenicity. Evaluation of SCB-1019 as part of a respiratory combination Trimer-Tagged PreF vaccine (RSV + hMPV ± PIV3) is also on track for Phase I clinical trial initiation in 2025.
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
GSK agrees US pricing framework to expand access to respiratory medicines
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema